DESCRIBED IN VERSION in Slovenian translation

• opisan v različici
• opisano v verziji
• opisano v različici

Examples of using Described in version in English and their translations into Slovenian

The MAH must ensure that the system of pharmacovigilance, as described in version 1.1 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Imetnik dovoljenja za promet z zdravilom mora pred prihodom zdravila na trg in dokler bo zdravilo na trgu in v uporabi zagotoviti vzpostavitev in delovanje sistema farmakovigilance, kot je opisan v verziji 1. 1v Modulu 1. 8. 1 vloge za pridobitev dovoljenja za promet z zdravilom.

Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 1.0 presented in Module 1.8.1. of the Marketing Authorisation,
Sistem farmakovigilance Imetnik dovoljenja za promet z zdravilom mora pred začetkom trženja zdravila vzpostaviti sistem farmakovigilance, kot je opisan v različici 1. 0 v modulu 1. 8. 1. vloge za pridobitev dovoljenja za promet z zdravilom,

The MAH must ensure that the system of pharmacovigilance, as described in version 4.0 November 2007 presented in Module 1.8.1. of the Marketing Authorisation Application,
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je opisan v različici 4. 0, november 2007, predstavljeni v modulu 1. 8. 1 vloge za pridobitev dovoljenja za promet z zdravilom,

Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 9.2 presented in Module 1.8.1. of the Marketing Authorisation Application,
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, opisan v različici 9. 2 v modulu 1. 8. 1 vloge za pridobitev dovoljenja za promet z zdravilom,

Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 2.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Sistem farmakovigilance Imetnik dovoljenja za promet mora zagotoviti, da pred dajanjem zdravila v promet in v času trženja zdravila deluje sistem farmakovigilance, kakor je opisan v različici 2. 0 v modulu 1. 8. 1. vloge za pridobitev dovoljenja za promet.

The MAH must ensure that the system of pharmacovigilance, as described in version 3 dated September 2007 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Sistem farmakovigilance Imetnik dovoljenja za promet z zdravilom mora pred začetkom trženja zdravila vzpostaviti sistem farmakovigilance, kot je opisan v različici 3 v modulu 1. 8. 1 vloge za pridobitev dovoljenja za promet z zdravilom sprejete septembra 2007, in ga vzdrževati ves čas trženja zdravila.

The MAH must ensure that the system of pharmacovigilance, as described in version 4.0(12 November 2007)
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da bo uveden sistem farmakovigilance, kot je opisan v različici 4. 0(12. november 2007),

The MAH must ensure that the system of pharmacovigilance as described in version 01(dated 4 May 2006)
DRUGI POGOJI Sistem farmakovigilance MAH mora zagotoviti, da je sistem farmakovigilance, opisan v različici 01(z dne 4. maja 2006),

Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 1 dated 05 December 2005 in Module 1.8.1. of the Marketing Authorisation,
Sistem farmakovigilance Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, opisan v različici z dne 5. decembra 2005 v modulu 1. 8. 1. dovoljenja za promet z zdravilom, vzpostavljen in da deluje,

The MAH must ensure that the system of pharmacovigilance, as described in version 3(dated 28 June 2007)
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je opisan v 3. različici(z dne 28. junija 2007) predstavljeni v modulu

Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 2.0, dated September 2006 presented in Module 1.8.1. of the Marketing Authorisation Application,
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je opisan v različici 2. 0, september 2006, predstavljen v modulu 1. 8. 1 vloge za pridobitev dovoljenja za promet z zdravilom, vzpostavljen

Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version V01(dated June 2006) presented in Module 1.8.1. of the Marketing Authorisation Application,
Sistem farmakovigilance Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je opisan v različici V01(junij 2006), predstavljen v modulu 1. 8. 1. vloge za pridobitev dovoljenja za promet z zdravilom,

Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 5.0 dated 09 October 2008 presented in Module 1.8.1. of the Marketing Authorisation Application,
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, opisan v različici 5. 0 z dne 09. oktobra 2008, predstavljen v modulu 1. 8. 1. vloge za pridobitev dovoljenja za promet, vzpostavljen in deluje,

Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 1.1(dated 8 November 2007) presented in Module 1.8.1. of the Marketing Authorisation Application,
Sistem farmakovigilance Imetnik dovoljenja za promet z zdravilom mora zagotoviti sistem farmakovigilance(opisan v različici 1. 1, predstavljen v modulu 1. 8. 1 vloge za pridobitev dovoljenja za promet,

Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 2 presented in Module 1.8.1. of the Marketing Authorisation Application
Sistem farmakovigilance Imetnik dovoljenja za promet z zdravilom mora pred za etkom trženja zdravila vzpostaviti sistem farmakovigilance, kot je opisan v razli ici 2 v modulu 1. 8. 1. vloge za pridobitev dovoljenja za promet z zdravilom,

The MAH must ensure that the system of pharmacovigilance, as described in version 2.0(28/ 02/ 2008) and included in the Type II variation(EMEA/ H/ C/ 000797/ II/ 0003) is in place and functioning before and whilst the product is on the market.
Imetnik dovoljenja za promet z zdravilom mora pred pričetkom trženja zdravila vzpostaviti delujoči sistem farmakovigilance, kot je opisan v različici 2. 0(28/ 02/ 2008) in vključen v spremembo tipa II(EMEA/ H/ C/ 000797/ II/ 0003), in ga vzdrževati ves čas trženja zdravila.

The MAH must ensure that the system of pharmacovigilance, as described in version 6.2 presented in Module 1.8.1. of the Marketing Authorisation Application,
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je opisan v različici 6. 2, predstavljeni v modulu 1. 8. 1. vloge za pridobitev dovoljenja za promet z zdravilom,

The MAH must ensure that the system of pharmacovigilance, as described in version 10.0 presented in Module 1.8.1. of the Marketing Authorisation Application,
Imetnik dovoljenja za promet mora zagotoviti, da je sistem farmakovigilance, kot je opisan v različici 10.0, predstavljeni v modulu 1.8.1 vloge za pridobitev dovoljenja za promet,

The MAH must ensure that the system of pharmacovigilance, as described in version 3.05(dated September 2009) presented in Module 1.8.1
Imetnik dovoljenja za promet mora zagotoviti, da je sistem farmakovigilance, kot je opisan v različici 3,05(September 2009), predstavljeni v modulu 1.8.1 vloge za pridobitev dovoljenja za promet,

Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 1.1(8 November 2007
Sistem farmakovigilance Imetnik dovoljenja za promet z zdravilom mora pred prihodom zdravila na trg in dokler bo zdravilo na trgu in v uporabi zagotoviti vzpostavitev in delovanje sistema farmakovigilance, kot je opisan v verziji 1. 1(8. november 2007